Aeon Biopharma, Inc.

AEON

NYSE; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001837607


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $5.6M
Warnings	dilution, short runway, thin data not computable: degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 30, 2026 225 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$0.18 2026-11-09; market equity $9.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States ("U.S.") market entry for debilitating medical conditions. On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) ("Old AEON") and Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra Acquisition Corp.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 0.4						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(503.7%)	(6.6%)	0.4	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 97.2					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(296.61)	(0.35)	99.3	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	0.49x	2.95x	95.0	826	2025-12-31
Growth and financing, sleeve percentile 85.2					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	(19.8%)	2.2%	84.0	694	2025-12-31
Net share issuance, one year	140.2%	2.5%	86.5	629	2026-03-23

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 140.2%
Short runway	cash runway is 3.0 months
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-09 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(64.7%)	(1.9%)	10
Distance from 52-week high	(86.6%)	(27.5%)	5
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(190.9%)	(1.0%)	3
Book value to price	(1.69)	0.27	1
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	20.8%	
Relative strength against the sector, log excess return	(1.21)	(0.19)	10

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$3.4M
Operating cash flow, four quarters	-$13.6M
Months of runway	3.0
Days since last periodic filing	90 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$192,930

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$39.2M	2025-12-31	2026-03-30	10-K	26-000019
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$17.3M	2025-12-31	2026-03-30	10-K	26-000019
3	assets	us-gaap:Assets	$5.6M	2025-12-31	2026-03-30	10-K	26-000019
4	assets	us-gaap:Assets	$3.1M	2024-12-31	2026-03-30	10-K	26-000019
5	current assets	us-gaap:AssetsCurrent	$3.4M	2025-12-31	2026-03-30	10-K	26-000019
6	current liabilities	us-gaap:LiabilitiesCurrent	$6.9M	2025-12-31	2026-03-30	10-K	26-000019
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$470.8M	2025-12-31	2026-03-30	10-K	26-000019
8	operating income	us-gaap:OperatingIncomeLoss	-$12.8M	2025-12-31	2026-03-30	10-K	26-000019
9	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	-$55.0M	2025-12-31	2026-03-30	10-K	26-000019
10	liabilities	us-gaap:Liabilities	$60.6M	2025-12-31	2026-03-30	10-K	26-000019
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4,000	2025-12-31	2026-03-30	10-K	26-000019
12	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$78,000	2025-12-31	2026-03-30	10-K	26-000019
13	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$39.2M	2025-12-31	2026-03-30	10-K	26-000019
14	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-30	10-K	26-000019
15	current assets	us-gaap:AssetsCurrent	$1.6M	2024-12-31	2026-03-30	10-K	26-000019
16	current liabilities	us-gaap:LiabilitiesCurrent	$14.1M	2024-12-31	2026-03-30	10-K	26-000019
17	assets	us-gaap:Assets	$6.8M	2023-12-31	2025-03-24	10-K	25-000022
18	assets	us-gaap:Assets	$10.8M	2022-12-31	2024-05-14	10-K/A	24-000059
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,303,058	2026-03-23	2026-03-30	10-K	26-000019
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	10,532,802	2025-03-21	2025-06-11	10-K/A	25-058531

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.